The earnings call highlighted ACADIA's strong revenue growth driven by DAYBUE and NUPLAZID sales, successful direct-to-consumer campaigns, and a robust pipeline expansion. However, there were concerns about increased SG&A expenses and inherent risks in pipeline development. Overall, the positive aspects of revenue growth and strategic initiatives outweigh the lowlights.

Company Guidance -

Q3 2025

During the ACADIA Pharmaceuticals conference call, the company provided financial guidance for 2025, highlighting several key metrics. ACADIA reported total revenue of $264.6 million for Q2, with $96.1 million from DAYBUE and $168.5 million from NUPLAZID. The company raised the lower end of its full-year NUPLAZID revenue guidance to $665-$690 million, reflecting strong commercial execution and positive momentum from a direct-to-consumer campaign. DAYBUE's sales grew by 14% year-over-year, with a 12-month persistency rate exceeding 50%. The call also noted a strategic expansion beyond Centers of Excellence, with 900 healthcare providers now prescribing DAYBUE. ACADIA's R&D pipeline includes nine disclosed programs, with expectations to initiate seven Phase II or III studies in 2025 and 2026, and five data readouts anticipated between 2025 and 2027. The company ended the quarter with a cash balance of $762 million and maintained confidence in achieving its financial targets, driven by disciplined execution and ongoing growth initiatives.

Strong Revenue Growth

ACADIA delivered total revenue of $264.6 million in Q2 2025, up 9% year-over-year, driven by DAYBUE and NUPLAZID sales.

DAYBUE Sales Increase

DAYBUE achieved $96.1 million in sales for Q2 2025, a 14% increase from the previous year, with unique patient shipments increasing.

NUPLAZID Revenue Growth

NUPLAZID's Q2 2025 revenue was $168.5 million, a 7% increase year-over-year, driven by improved prescription volumes.

Pipeline Expansion

ACADIA is advancing its pipeline with 9 disclosed programs, including anticipated Phase II and III studies and readouts from 2025 to 2027.

Successful Direct-to-Consumer Campaigns

The direct-to-consumer campaigns for both DAYBUE and NUPLAZID are driving increased consumer engagement and new prescriptions.

ACADIA Pharmaceuticals (ACAD) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

ACAD Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Nov 11, 2025	2025 (Q3)	0.14 / -	0.2	―	―	―
Aug 06, 2025	2025 (Q2)	0.14 / 0.16	0.2	-20.00% (-0.04)
May 07, 2025	2025 (Q1)	0.09 / 0.11	0.1	10.00% (<+0.01)
Feb 26, 2025	2024 (Q4)	0.22 / 0.86	0.28	207.14% (+0.58)
Nov 06, 2024	2024 (Q3)	0.14 / 0.20	-0.4	150.00% (+0.60)
Aug 06, 2024	2024 (Q2)	0.18 / 0.20	0.01	1900.00% (+0.19)
May 08, 2024	2024 (Q1)	0.05 / 0.10	-0.27	137.04% (+0.37)
Feb 27, 2024	2023 (Q4)	0.29 / 0.28	-0.26	207.69% (+0.54)
Nov 02, 2023	2023 (Q3)	-0.45 / -0.40	-0.17	-135.29% (-0.23)
Aug 02, 2023	2023 (Q2)	-0.10 / 0.01	-0.21	104.76% (+0.22)

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

ACAD Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Aug 06, 2025	$23.80	$24.40	+2.52%
May 07, 2025	$14.81	$16.93	+14.31%
Feb 26, 2025	$19.00	$19.34	+1.79%
Nov 06, 2024	$15.79	$17.20	+8.93%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does ACADIA Pharmaceuticals (ACAD) report earnings?

ACADIA Pharmaceuticals (ACAD) is schdueled to report earning on Nov 11, 2025, After Close (Confirmed).

What is ACADIA Pharmaceuticals (ACAD) earnings time?

ACADIA Pharmaceuticals (ACAD) earnings time is at Nov 11, 2025, After Close (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is ACAD EPS forecast?

ACAD EPS forecast for the fiscal quarter 2025 (Q3) is 0.14.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing